Journal of Gastrointestinal Cancer

, Volume 38, Issue 2–4, pp 119–126 | Cite as

Risk of Other Cancers in Individuals with a Family History of Pancreas Cancer

  • Michele L. Cote
  • Maryjean Schenk
  • Ann G. Schwartz
  • Fawn D. Vigneau
  • Margaret Kinnard
  • Joel K. Greenson
  • Jon P. Fryzek
  • Gui Shuang Ying
  • David H. Garabrant



Inherited predisposition to pancreas cancer accounts for approximately 10% of cases. Familial aggregation may be influenced by shared environmental factors and shared genes. We evaluate whether a family history of pancreas cancer is a risk factor for ten specified cancers in first-degree relatives: bladder, breast, colon, head and neck, lung, lymphoma, melanoma, ovary, pancreas, and prostate.


Risk factor data and cancer family history were obtained for 1,816 first-degree relatives of pancreas cancer case probands (n = 247) and 3,157 first-degree relatives of control probands (n = 420). Unconditional logistic regression models using generalized estimating equations were used to estimate odds ratios (ORs), and 95% confidence intervals of having a first-degree relative a specified cancer.


A family history of pancreas cancer was associated with a doubled risk of lymphoma (OR = 2.83, 95% CI = 1.02–7.86) and ovarian cancer (OR = 2.25, 95% CI = 0.77–6.60) among relatives after adjustment. Relatives with a family history of early-onset pancreas cancer in a proband had a sevenfold increased risk of lymphoma (OR = 7.31, 95% CI = 1.45 to 36.7). Relatives who ever smoked and had a family history of pancreas cancer had a fivefold increased risk of ovarian cancer (OR = 4.89, 95% CI = 1.16–20.6).


Family history assessment of cancer risk should include all cancers. Assessment of other known and suspected risk factors in relatives will improve risk evaluation. As screening and surveillance methods are developed, identifying those at highest risk is crucial for a successful screening program.


pancreas cancer lymphoma ovarian cancer family history of pancreas cancer smoking young age at cancer diagnosis genetic risk 



This research was supported by the National Institute of Environmental Health Sciences RO1 ES07129 and the National Cancer Institute RC25-CA7716 and NO1-CN-65064, and by gifts from the Schreiber Foundation for Cancer Research, the Marlin Pemberton Fund, and a gift in memory of Adrian Mayer, MD.


  1. 1.
    Society AC. Cancer facts and figures—2006. Atlanta, Georgia: American Cancer Society; 2006.Google Scholar
  2. 2.
    Hezel AF, Kimmelman AC, Stanger BZ, Bardeesy N, Depinho RA. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2006;20(10):1218–49. doi: 10.1101/gad.1415606.PubMedCrossRefGoogle Scholar
  3. 3.
    Ries L, Harkins D, Krapcho M, et al. SEER cancer statistics review, 1975–2003. Bethesda, MD: National Cancer Institute; 2006.Google Scholar
  4. 4.
    Lowenfels AB, Maisonneuve P. Risk factors for pancreatic cancer. J Cell Biochem 2005;95(4):649–56. doi: 10.1002/jcb.20461.PubMedCrossRefGoogle Scholar
  5. 5.
    Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006;20(2):197–209. doi: 10.1016/j.bpg.2005.10.001.PubMedCrossRefGoogle Scholar
  6. 6.
    Schottenfeld D, Fraumeni JF, Jr., eds. Cancer epidemiology and prevention. 3rd ed. Oxford Press; 2006.Google Scholar
  7. 7.
    Lynch HT, Smyrk T, Kern SE, et al. Familial pancreatic cancer: a review. Semin Oncol 1996;23(2):251–75.PubMedGoogle Scholar
  8. 8.
    Ehrenthal D, Haeger L, Griffin T, Compton C. Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature. Cancer 1987;59(9):1661–4. doi: 10.1002/1097-0142(19870501)59:9<1661::AID-CNCR2820590923>3.0.CO;2-H.PubMedCrossRefGoogle Scholar
  9. 9.
    Friedman JM, Fialkow PJ. Familial carcinoma of the pancreas. Clin Genet 1976;9(5):463–9.PubMedGoogle Scholar
  10. 10.
    Ghadirian P, Boyle P, Simard A, Baillargeon J, Maisonneuve P, Perret C. Reported family aggregation of pancreatic cancer within a population-based case-control study in the Francophone community in Montreal, Canada. Int J Pancreatol 1991;10(3–4):183–96.PubMedGoogle Scholar
  11. 11.
    Tersmette AC, Petersen GM, Offerhaus GJ, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001;7(3):738–44.PubMedGoogle Scholar
  12. 12.
    Schenk M, Schwartz AG, O'Neal E, et al. Familial risk of pancreatic cancer. J Natl Cancer Inst 2001;93(8):640–4. doi: 10.1093/jnci/93.8.640.PubMedCrossRefGoogle Scholar
  13. 13.
    Hartge P, Brinton LA, Rosenthal JF, Cahill JI, Hoover RN, Waksberg J. Random digit dialing in selecting a population-based control group. Am J Epidemiol 1984;120(6):825–33.PubMedGoogle Scholar
  14. 14.
    Kirsner RS, Federman DG. The epidemiology of non-Hodgkin’s lymphoma. Conn Med 1996;60(10):579–82.PubMedGoogle Scholar
  15. 15.
    Grulich AE, Vajdic CM, Cozen W. Altered immunity as a risk factor for non-Hodgkin lymphoma. Cancer Epidemiol Biomark Prev 2007;16(3):405–8. doi: 10.1158/1055-9965.EPI-06-1070.CrossRefGoogle Scholar
  16. 16.
    Engels EA. Infectious agents as causes of non-Hodgkin lymphoma. Cancer Epidemiol Biomark Prev 2007;16(3):401–4. doi: 10.1158/1055-9965.EPI-06-1056.CrossRefGoogle Scholar
  17. 17.
    Krishnan B, Morgan GJ. Non-Hodgkin lymphoma secondary to cancer chemotherapy. Cancer Epidemiol Biomark Prev 2007;16(3):377–80. doi: 10.1158/1055-9965.EPI-06-1069.CrossRefGoogle Scholar
  18. 18.
    Pottern LM, Linet M, Blair A, et al. Familial cancers associated with subtypes of leukemia and non-Hodgkin’s lymphoma. Leuk Res 1991;15(5):305–14. doi: 10.1016/0145-2126(91)90005-E.PubMedCrossRefGoogle Scholar
  19. 19.
    McWilliams RR, Rabe KG, Olswold C, De Andrade M, Petersen GM. Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. Cancer 2005;104(2):388–94. doi: 10.1002/cncr.21166.PubMedCrossRefGoogle Scholar
  20. 20.
    Silverman DT, Schiffman M, Everhart J, et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999;80(11):1830–7. doi: 10.1038/sj.bjc.6690607.PubMedCrossRefGoogle Scholar
  21. 21.
    Runnebaum IB, Stickeler E. Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 2001;127(2):73–9. doi: 10.1007/s004320000153.PubMedCrossRefGoogle Scholar
  22. 22.
    Franks AL, Lee NC, Kendrick JS, Rubin GL, Layde PM. Cigarette smoking and the risk of epithelial ovarian cancer. Am J Epidemiol 1987;126(1):112–7.PubMedGoogle Scholar
  23. 23.
    Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Cigarette smoking and increased risk of mucinous epithelial ovarian cancer. Am J Epidemiol 2004;159(2):133–9. doi: 10.1093/aje/kwh015.PubMedCrossRefGoogle Scholar
  24. 24.
    Kerber RA, Slattery ML. The impact of family history on ovarian cancer risk. The Utah Population Database. Arch Intern Med 1995;155(9):905–12. doi: 10.1001/archinte.155.9.905.PubMedCrossRefGoogle Scholar
  25. 25.
    Schutte M, Rozenblum E, Moskaluk CA, et al. An integrated high-resolution physical map of the DPC/BRCA2 region at chromosome 13q12. Cancer Res 1995;55(20):4570–4.PubMedGoogle Scholar
  26. 26.
    Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378(6559):789–92. doi: 10.1038/378789a0.PubMedCrossRefGoogle Scholar
  27. 27.
    Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996;56(23):5360–4.PubMedGoogle Scholar
  28. 28.
    Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 2002;62(13):3789–93.PubMedGoogle Scholar
  29. 29.
    Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003;95(3):214–21.PubMedCrossRefGoogle Scholar
  30. 30.
    The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999;91(15):1310–6. doi: 10.1093/jnci/91.15.1310.CrossRefGoogle Scholar
  31. 31.
    van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 2005;42(9):711–9. doi: 10.1136/jmg.2004.028829.PubMedCrossRefGoogle Scholar
  32. 32.
    Maitra A, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Best Pract Res Clin Gastroenterol 2006;20(2):211–26. doi: 10.1016/j.bpg.2005.10.002.PubMedCrossRefGoogle Scholar
  33. 33.
    Thompson D, Easton DF. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002;94(18):1358–65.PubMedGoogle Scholar
  34. 34.
    Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz–Jeghers syndrome. Gastroenterology 2000;119(6):1447–53. doi: 10.1053/gast.2000.20228.PubMedCrossRefGoogle Scholar
  35. 35.
    Goldstein AM, Fraser MC, Struewing JP, et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995;333(15):970–4. doi: 10.1056/NEJM199510123331504.PubMedCrossRefGoogle Scholar
  36. 36.
    Parker JF, Florell SR, Alexander A, DiSario JA, Shami PJ, Leachman SA. Pancreatic carcinoma surveillance in patients with familial melanoma. Arch Dermatol 2003;139(8):1019–25. doi: 10.1001/archderm.139.8.1019.PubMedCrossRefGoogle Scholar
  37. 37.
    Giardiello FM, Offerhaus GJ, Lee DH, et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut 1993;34(10):1394–6. doi: 10.1136/gut.34.10.1394.PubMedCrossRefGoogle Scholar
  38. 38.
    Lynch HT, Voorhees GJ, Lanspa SJ, McGreevy PS, Lynch JF. Pancreatic carcinoma and hereditary nonpolyposis colorectal cancer: a family study. Br J Cancer 1985;52(2):271–3.PubMedGoogle Scholar
  39. 39.
    Duker NJ. Chromosome breakage syndromes and cancer. Am J Med Genet 2002;115(3):125–9. doi: 10.1002/ajmg.10688.PubMedCrossRefGoogle Scholar
  40. 40.
    Swift M, Chase CL, Morrell D. Cancer predisposition of ataxia-telangiectasia heterozygotes. Cancer Genet Cytogenet 1990;46(1):21–7. doi: 10.1016/0165-4608(90)90004-T.PubMedCrossRefGoogle Scholar
  41. 41.
    Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangectasia gene with a product similar to PI-3 kinase. Science 1995;268:1749–53. doi: 10.1126/science.7792600.PubMedCrossRefGoogle Scholar
  42. 42.
    Ball LG, Xiao W. Molecular basis of ataxia telangiectasia and related diseases. Acta Pharmacol Sin 2005;26(8):897–907. doi: 10.1111/j.1745-7254.2005.00165.x.PubMedCrossRefGoogle Scholar
  43. 43.
    Kelsey J, Whittemore A, Evans A, Thompson W. Methods in observational epidemiology. 2nd ed. New York: Oxford University Press; 1996.Google Scholar
  44. 44.
    Murff HJ, Spigel DR, Syngal S. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 2004;292(12):1480–9. doi: 10.1001/jama.292.12.1480.PubMedCrossRefGoogle Scholar
  45. 45.
    Theis B, Boyd N, Lockwood G, Tritchler D. Accuracy of family cancer history in breast cancer patients. Eur J Cancer Prev 1994;3(4):321–7. doi: 10.1097/00008469-199407000-00004.PubMedCrossRefGoogle Scholar
  46. 46.
    McLaughlin JK, Mandel JS, Mehl ES, Blot WJ. Comparison of next-of-kin with self-respondents regarding questions on cigarette, coffee, and alcohol consumption. Epidemiology 1990;1(5):408–12. doi: 10.1097/00001648-199009000-00013.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2008

Authors and Affiliations

  • Michele L. Cote
    • 1
    • 2
  • Maryjean Schenk
    • 1
    • 3
  • Ann G. Schwartz
    • 1
    • 2
  • Fawn D. Vigneau
    • 1
  • Margaret Kinnard
    • 4
    • 5
  • Joel K. Greenson
    • 6
  • Jon P. Fryzek
    • 4
    • 7
  • Gui Shuang Ying
    • 4
    • 8
    • 9
  • David H. Garabrant
    • 4
  1. 1.Barbara Ann Karmanos Cancer InstitutePopulation Studies and PreventionDetroitUSA
  2. 2.Department of Internal MedicineWayne State UniversityDetroitUSA
  3. 3.Department of Family Medicine and Public Health SciencesWayne State UniversityDetroitUSA
  4. 4.Department of Environmental Health Sciences, School of Public HealthUniversity of MichiganAnn ArborUSA
  5. 5.Division of Gastroenterology, Department of Medicine, School of MedicineCase Western UniversityClevelandUSA
  6. 6.Department of Pathology, School of MedicineUniversity of MichiganAnn ArborUSA
  7. 7.Amgen, Inc.Thousand OaksUSA
  8. 8.Department of Biostatistics, School of Public HealthUniversity of MichiganAnn ArborUSA
  9. 9.Department of BiostatisticsUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations